LONDON, March 28, 2017 /PRNewswire/ --
PharmaBoardroom today releases its new 56-page Healthcare & Life Sciences Review Ireland 2017.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Ireland; a nation that stands poised to cement its position as a premier pharmaceuticals power, not just within Europe, but globally. In addition to its blossoming R&D infrastructure, a large number of major healthcare, pharma, and medtech MNCs base manufacturing operations on the Emerald Isle due to its favorable taxation policies, incredible concentration of talent, membership of the EU single market, and easy access to a wide range of foreign markets. Despite its relatively small size, Ireland is the largest net exporter of pharmaceuticals in the EU and seventh largest globally, and could benefit significantly from the UK's Brexit decision.
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on Ireland's healthcare and pharma sectors.
Features
Featured topics include:
The report features in-depth interviews with:
"Ireland is actually the most efficient EU country in terms of innovation output"
Mark Ferguson, Science Foundation Ireland
"[Ireland has] proven that, given the opportunity, we will deliver. The pharma industry is not in Ireland by accident"
Noel Heaney, BMS Biologics
"There are so many clusters of expertise in the API, pharma, biopharma and medtech sectors and that is fantastic because it fosters talent development"
Gearoid McDermott, Amneal
"Within Europe, there is clear recognition that Ireland has a strong life sciences ecosystem. This translates into the European market: when these pharma companies need partners across Europe, they approach their Irish partners first"
Donal O'Callaghan, Callaghan Engineering
Click here to register and download the report.
SOURCE PharmaBoardroom
Advertisement
PharmaBoardroom today releases its new 56-page Healthcare & Life Sciences Review Ireland 2017.
This report offers companies, investors, policymakers, and stakeholders crucial insight into Ireland; a nation that stands poised to cement its position as a premier pharmaceuticals power, not just within Europe, but globally. In addition to its blossoming R&D infrastructure, a large number of major healthcare, pharma, and medtech MNCs base manufacturing operations on the Emerald Isle due to its favorable taxation policies, incredible concentration of talent, membership of the EU single market, and easy access to a wide range of foreign markets. Despite its relatively small size, Ireland is the largest net exporter of pharmaceuticals in the EU and seventh largest globally, and could benefit significantly from the UK's Brexit decision.
Advertisement
The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on Ireland's healthcare and pharma sectors.
Features
Featured topics include:
- Indigenous Irish Innovation
- Moving Up the Manufacturing Value Chain
- Maintaining the Talent Pipeline
- The Stout Irish Market: Modest but Strategic
- Stakeholder Collaboration
- Digitalization
The report features in-depth interviews with:
- Charles Flanagan TD, Minister for Foreign Affairs & Trade
- John Halligan TD, Minister of State for Training & Skills
- Barry Heavey, IDA
- Mary Harney, European Steering Group on Sustainable Healthcare
- Tony O'Brien, HSE
- Mark Ferguson, Science Foundation Ireland
"Ireland is actually the most efficient EU country in terms of innovation output"
Mark Ferguson, Science Foundation Ireland
"[Ireland has] proven that, given the opportunity, we will deliver. The pharma industry is not in Ireland by accident"
Noel Heaney, BMS Biologics
"There are so many clusters of expertise in the API, pharma, biopharma and medtech sectors and that is fantastic because it fosters talent development"
Gearoid McDermott, Amneal
"Within Europe, there is clear recognition that Ireland has a strong life sciences ecosystem. This translates into the European market: when these pharma companies need partners across Europe, they approach their Irish partners first"
Donal O'Callaghan, Callaghan Engineering
Click here to register and download the report.
SOURCE PharmaBoardroom
